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To assess the implication of the genetic background of
Escherichia coli strains in the emergence of extended-
spectrum β-lactamases (ESBL), 55 TEM-, 52 CTX-M-, and
22 SHV-type ESBL-producing clinical isolates involved in
various extraintestinal infections or colonization were stud-
ied in terms of phylogenetic group, virulence factor (VF)
content (pap,  sfa/foc,  hly, and aer genes), and fluoro-
quinolone resistance. A factorial analysis of correspon-
dence showed that SHV type, and to a lesser extent TEM
type, were preferentially observed in B2 phylogenetic group
strains that exhibited numerous VFs but were fluoro-
quinolone-susceptible, whereas the newly emerged CTX-M
type was associated with the D phylogenetic group strains
that lacked VF but were fluoroquinolone-resistant. Thus,
the emergence of ESBL-producing E. coli seems to be the
result of complex interactions between the type of ESBL,
genetic background of the strain, and selective pressures in
ecologic niches.
E
xtended-spectrum β-lactamases (ESBL) that mediate
resistance to oxyimino-cephalosporins, such as cefo-
taxime, aztreonam, and ceftazidime, are now observed
worldwide in all species of Enterobacteriaceae (1).
Traditionally, ESBLs are derived by point mutation from
the common TEM and SHV-1 β-lactamases. However,
recently, new families of ESBLs have been described (2).
The CTX-M-type ESBLs have become particularly wide-
spread and are mainly found in strains of Salmonella and
Escherichia coli (3,4). These enzymes probably evolved
from chromosomal β-lactamases of Kluyvera spp. by gene
transposition from mobile elements and mutation (5,6).
ESBLs are usually described as acquired β-lactamases that
are encoded mainly by genes located on plasmids. Some
ESBL-encoding genes are located within transposons or
integrons, which facilitates transfer between organisms.
ESBL-producing organisms are responsible for nosocomi-
al infections, and many hospitals have experienced out-
breaks (1,2,7). The lower digestive tract of colonized
patients has been recognized as the major source of ESBL-
producing organism (2,8). These organisms pose a thera-
peutic challenge, since they are frequently resistant to
other kinds of antimicrobial drugs, including aminoglyco-
sides, quinolones, and cotrimoxazole (2).
E. coli in humans is a commensal inhabitant of the gas-
trointestinal tract. It can also cause various intestinal and
extraintestinal diseases (9). Strains causing infections har-
bor numerous virulence factors encoded on plasmids, bac-
teriophages, or the bacterial chromosome within
pathogenicity islands (9). Several studies have shown that
pathogenic E. coli strains may be derived from commensal
strains by acquiring chromosomal or extrachromosomal
virulence operons (10,11). Phylogenetic analyses have
shown that E. coli strains fall into 4 main phylogenetic
groups (A, B1, B2, and D) (12,13). Although virulence
determinants are considered to be mobile, a link between
strain phylogeny and virulence has been reported. Virulent
extraintestinal strains belong mainly to group B2 and, to a
lesser extent, to group D, whereas most commensal strains
belong to groups Aand B1. Strains of phylogenetic groups
B2 and D often carry virulence determinants that are lack-
ing in group A and B1 strains (10,14–17). In addition, a
trade-off between resistance and virulence has been
observed. Prevalence of antimicrobial resistance was
shown to be greater in non-B2 phylogenetic group strains
(18). In urinary tract infections, fluoroquinolone-resistant
E. coli represented predominantly low-virulence phyloge-
netic groups A and B1 (19). These resistant strains were
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The intrinsic virulence potential of ESBL-producing E.
coli is unknown. They may represent traditional virulence
clones of extraintestinal pathogenic E. coli (ExPEC) or
low-virulence opportunists whose ability to cause disease
is largely limited to compromised hosts, in which antimi-
crobial resistance might provide relevant selective advan-
tage. To assess the relationships between the genetic
background of the strains and the presence of an ESBL, we
analyzed a collection of ESBL-producing E. coli clinical
isolates involved in various extraintestinal infections or in
colonization in terms of phylogenetic grouping, virulence
determinant content, and fluoroquinolone resistance.
Material and Methods
Bacterial Strains
We collected 157 E. coli isolates from clinical samples
on the basis of their positive double-disk synergy test from
1997 to 2002 in different areas in France: Paris area (4 hos-
pitals), Brest, and Amiens. From these isolates 129 strains
were analyzed on the basis of 3 criteria: 1) the strains pro-
duced an ESBL, 2) the strains were epidemiologically unre-
lated, and 3) the strains were unambiguously classified as
responsible for infection or colonization. ESBLs were char-
acterized by isoelectric focusing with ceftriaxone and peni-
cillin as substrates (7), specific polymerase chain reaction
(PCR) amplification, and direct sequencing of PCR prod-
ucts. The oligonucleotide primer sets specific for the β-lac-
tamase gene (bla) amplification and sequencing were taken
from the literature (blaTEM and blaSHV) (22) or designed in
this study (blaCTX-M) (Table 1). As the family of CTX-M
ESBLs belongs to 4 clusters on the basis of their protein
sequences, the CTX-M-1 cluster (CTX-M-1, CTX-M-3,
CTX-M-10, CTX-M-12, CTX-M-15), the CTX-M-2 clus-
ter (CTX-M-2, CTX-M-4 to CTX-M-7, Toho-1), the CTX-
M-9 cluster (CTX-M-9, CTX-M-14, CTX-M-16,
CTX-M-18, CTX-M-19, Toho-2), and the CTX-M-8 clus-
ter, specific primers for each cluster of the CTX-M family
were designed. PCR products of blaTEM were subjected to
direct sequencing to identify TEM-ESBLs, only when iso-
lates produced a single β-lactamase indicated by isoelectric
focusing. For isolates carrying a second β-lactamase of pI
5.4 or 5.6 shown by penicillin only (putative TEM-1 or
TEM-2 β-lactamase), sequences were obtained after plas-
mid transfer into E. coli K-12 J53-2 rifr (23). PCR product
sequences were then compared to reported ESBL
sequences and assigned to specific types or clusters. To
identify any epidemiologic relationship between the strains,
they were compared by using enterobacterial repetitive
intergenic consensus (ERIC)-PCR with ERIC1 and ERIC2
as primers (24,25). When strains had identical elec-
trophoretic profiles with both ERIC1 and ERIC2 primers,
they were considered identical, and only 1 isolate per elec-
trophoretic profile type was selected for further analysis.
Among the collection of 129 strains selected for the study,
86 strains were involved in infections (urinary tract infec-
tion [UTI]: 64, bacteriemia: 7, pus production from miscel-
laneous infections: 15), and 43 strains were isolated from
colonization (rectal samples: 39, gastric aspirate: 1, abdom-
inal drainage: 1, vaginal sample: 1, tracheal aspirate: 1)
(Table 2). The collection included 55 strains that produced
a TEM-type ESBL, 22 strains produced a SHV-type ESBL,
and 52 strains produced a CTX-M type ESBL (Table 2).
Susceptibility Testing, Phylogenetic Grouping, and
Virulence Factors
Susceptibility to ciprofloxacin was tested by the disk
diffusion technique according to the guidelines of the
Antibiogram Committee of the French Society for
Microbiology (www.sfm.asso.fr) with MIC criteria of <1
mg/L (diameter  >22 mm) used to define susceptibility.
Phylogenetic grouping of the E. coli isolates was deter-
mined by a PCR-based method developed by Clermont et
al. (26) that uses a combination of 3 DNA markers (chuA,
yjaA, and an anonymous DNA fragment, TspE4.C2).
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of presence or absence of the 3 DNA fragments: chuA–,
TspE4.C2–, group A; chuA–, yjaA–, Tspe4.C2+, group B1;
chuA+, yjaA+, group B2; chuA+, yjaA–, group D. Because
2 possible profiles can be obtained for the groups A, B2,
and D, each was subdivided as follows: chuA–,  yjaA–,
Tspe4.C2–, group A subgroup A0;  chuA–,  yjaA+,
Tspe4.C2–, group A subgroup A1;  chuA+,  yjaA+,
Tspe4.C2–, group B2 subgroup B22;  chuA+,  yjaA+,
Tspe4.C2+, group B2 subgroup B23;  chuA+,  yjaA–,
Tspe4.C2–, group D subgroup D1;  chuA+,  yjaA–,
Tspe4.C2+, group D subgroup D2. Virulence genes (pap,
sfa/foc,  hly,  aer) were detected from DNA by PCR as
described previously (15,27). These genes code for 2
adhesins (pyelonephritis-associated pili system and S fim-
brial adhesin), 1 toxin (α-hemolysin), and 1 iron captation
system. These genes are good representatives of the intrin-
sic extraintestinal virulence of the strains (28).
Statistical Analysis
Data were summarized in 2 two-way tables, and each
table had 129 rows, one for each E. coli strain. The first
table had 16 columns corresponding to the variables, ori-
gin of the strains, phylogenetic group or subgroup, type of
ESBL, and virulence factors. The second table had 12
columns corresponding to the variables, phylogenetic
groups, type of ESBL, and resistance to ciprofloxacin. For
each column, each strain was coded as a binary code: pres-
ent = 2, absent = 1. A factorial analysis of correspondence
(FAC) (29) was conducted from this table with SPAD.N
software (Cisia, Saint Mandé, France). To confirm the sig-
nificance of the correlation observed with FAC, χ² tests
were carried out. 
Results
Characterization of ESBL Strains
Among the 129 E. coli strains analyzed, phylogenetic
group B2, which is the source of most ExPEC clones, was
represented by 36.4 % of the strains (8.5% were subgroup
B22 and 27.9% were subgroup B23). Phylogenetic group
D, which is also a source of ExPEC but to a lesser extent,
was represented by 25.5% of the strains (17% were sub-
group D1 and 8.5% were subgroup D2). Of the remaining
strains, phylogenetic groups Aand B1 were represented by
27.9% (9.3% were subgroup A0 and 18.6% were subgroup
A1) and 10 % of the strains, respectively. The virulence
determinants most represented in the collection were aer
and pap, with 53 (41%) and 38 (29.5%) strains carrying
these genes, respectively. Less prevalent were sfa/foc and
hly determinants, with only 18 (14%) and 19 (15%) posi-
tive strains, respectively. Fluoroquinolone resistance was
present in 34.8% of the strains.
ESBL-producing strains were found in all E. coli phy-
logenetic groups. Of the strains, 60% and 24% harbored at
least 1 or 2 extraintestinal virulence determinants, respec-
tively. Coresistance to fluoroquinolones was frequent.
Multidimensional Analysis
To assess relationships between phylogenetic groups,
VFs, type of ESBL produced, and origin of the strains
(infection or colonization), a FAC was constructed with
the 129 E. coli strains as individuals and the 16 character-
istics as qualitative variables. Projections of the variables
on the plane F1/F2 (Figure A), which accounted for 34.5%
of the total variance, showed a correlation between the
type of ESBL produced and several phylogenetic
group/subgroups of E. coli. Thus, SHV type and subgroup
B23 are projected on the positive values of F1 and negative
values of F2, whereas TEM type and subgroup B22 are
projected on the positive values of F1 and F2. CTX-M type
and subgroup D2 are projected on the negative values of F1
and F2. Correlation between SHV type and subgroup B23
was confirmed by χ²tests (p < 0.001) and the CTX-M type
and the subgroup D2 (p < 0.001) (Table 3).
As previously reported, sfa/foc and hly VFs were exclu-
sively found in strains of the subgroups B22 and B23
(10,16). Pairwise comparisons between individual sub-
groups showed that subgroups B22 and B23 each had mean
VF scores (1.45 and 1.8, respectively) significantly higher
than either phylogenetic groups and subgroups A0, A1, B1,
D1, or D2 (p < 0.02 for all comparisons), but they were not
significantly different from one another. Likewise phylo-
genetic groups and subgroups A0, A1, B1, D1, and D2 were
not significantly different from one another with respect to
mean VF scores (mean scores 0.5, 0.66, 0.54, 0.5, and
0.63, respectively). When the type of ESBL produced was
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ducing strains (mean score = 1.8) than in TEM-producing
strains (mean score = 0.96). The lowest frequency was
found in the CTX-M-producing strains (mean score = 0.6).
FAC stressed these 2 observations, as it showed that the
pap, sfa/foc, and hly VFs were projected on the positive
values of the first axis with the subgroup B23 and the SHV
type. The correlation between SHV type and the presence
of the 3 VFs was also confirmed by χ² tests (pap, p < 0.01;
sfa/foc, p < 0.001; hly, p < 0.001). Aerobactin was found in
all the phylogenetic groups and subgroups, and no correla-
tion was observed with the FAC (Table 4).
Projection of the colonization and infection variables
on the plane showed that they were clearly distinguished
by the first factor and that there was a correlation with
some phylogenetic groups (Figure A). The colonization
characteristic was projected on the positive values of F1
with phylogenetic subgroups A0 and D1. The association
was close to significance (A0, p = 0.05; D1, p = 0.06):
strains of subgroups A0 and D1 were isolated more fre-
quently from colonization (relative risk [RR] of 3.15 and
2.34, respectively) (Table 3). If we consider the clones usu-
ally to be the major source of ExPEC, strains of the sub-
group B22 were equally distributed among the strains
responsible for infection or colonization (8.1% versus
9.3%), but strains of subgroup B23 were more numerous
among the strains responsible for infection than for colo-
nization (32.5% versus 18.6%); the correlation was close
to significance (p = 0.09, RR = 2.11) (Table 3). TEM type
was also projected on the positive values of F2 with the
colonization characteristic, and the χ2 test confirmed the
correlation (p = 0.03).
The mean VF score of the strains responsible for infec-
tion was significantly higher (p = 0.03) than the mean VF
score of the strains responsible for colonization (1.1 and
0.76, respectively). However, when each VF was consid-
ered, only the frequency of aerobactin was significantly
higher among the strains responsible for infection (p =
0.03) than the strains responsible for colonization.
To assess the relationships between phylogenetic
groups and subgroups, ESBL type, and resistance to fluo-
roquinolones, a second FAC was performed, taking into
account only these variables (Figure B). Projection of the
variables on the plane F1/F2, which accounted for 34% of
the total variance, showed a correlation between resistance
to ciprofloxacin and type of ESBL produced. Thus, the
ciprofloxacin-resistant characteristic was projected on the
negative values of the first factor with CTX-M-type, and
the ciprofloxacin-susceptible characteristic was projected
on the positive values of the first factor with TEM and
SHV types. Significant differences were observed between
the rate of resistance to fluoroquinolones among the CTX-
M- (51.9%) and among the SHV- and TEM-producing
strains (13.6% and 27.7%, respectively): CTX-M type /
SHV type, p = 0.002 and CTX-M type / TEM type, p =
0.009. FAC stressed also the correlation between the sub-
group D1 and the resistance to ciprofloxacin, which were
projected together on the negative values of the first factor
and on the positive values of the second factor. The corre-
lation was confirmed by the χ² test (p = 0.03). Strains of
phylogenetic subgroup D1 had the highest resistance rate
(54%), and strains of subgroups B22, B23, and A0 had the
lowest resistance rates (18%, 25%, and 25%, respectively).
Group/subgroups B1, D2, and A1 had ciprofloxacin resist-
ance rates of 30.7%, 36%, and 45%, respectively. No sig-
nificant difference was seen in the frequencies of
ciprofloxacin resistance among strains from infection or
colonization (38.3% versus 27.9%). The mean VF score of
the ciprofloxacin-susceptible strains was significantly
higher (p < 0.001) than the one of the ciprofloxacin-
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Figure. Graphic representation of the results of the factorial analy-
sis of correspondence carried out with whole data from the 129
Escherichia coli strains. A) Projections of the variables on the
F1/F2 plane: phylogenetic group and subgroups (A0, A1, B1, B22,
B23, D1, and D2), type of extended-spectrum β-lactamase (ESBL)
(TEM, SHV, CTX-M), virulence factors (pap, sfa, hly, aer), and the
source infection (inf) or colonization (col). B) Projections of the
variables on the F1/F2 plane: phylogenetic group and subgroups
(A0, A1, B1, B22, B23, D1, and D2), type of ESBL (TEM, SHV, CTX-
M), and ciprofloxacin resistance (cipR) or the ciprofloxacin sus-
ceptibility (cipS).resistant strains (1.2 and 0.6, respectively) (Table 4). We
found hly and sfa/foc exclusively in ciprofloxacin-suscep-
tible strains, and the frequency of pap was significantly
higher among ciprofloxacin-susceptible strains (p = 0.04)
than among ciprofloxacin-resistant strains. No difference
was observed in the frequency of aerobactin between the 2
groups (Table 4). Although the frequency of CTX-M type
was higher among UTI strains than among non-UTI strains
(Table 2), FAC analysis and χ² tests did not show any sig-
nificant association between UTI strains, phylogenetic
group or subgroup, individual VFs, and ciprofloxacin
resistance (data not shown), which could explain some of
the previously observed correlations.
Therefore, strains harboring ESBL of SHV and TEM
types belonged preferentially to the B2 phylogenetic
group. They possessed extraintestinal VFs, but ESBL
TEM-type strains were more likely to be isolated from
cases of colonization; they were also susceptible to fluoro-
quinolones. On the other hand, strains harboring ESBL of
CTX-M type were associated with D2 phylogenetic sub-
group, had few VFs, but were resistant to fluoro-
quinolones.
Discussion
This study was designed to assess the role of the genetic
background of strains of E. coli in the emergence of ESBL.
Strains were sampled from hospitals in several distant areas,
which allowed us to build up a collection of strains produc-
ing variants of the most prevalent ESBL types. Thus 3
groups of ESBL-types were collected, TEM-, SHV-, and
CTX-M-type, having enough strains in each group to be
compared. Spread of clones of ESBL-producing organisms
can occur from cross-contamination among patients
(2,7,23). Therefore, to avoid redundant strains, we used
ERIC-PCR as a typing method, and strains with similar pro-
files were eliminated.
Several studies suggested that extraintestinal pathogen-
ic E. coli strains are mostly derived from the B2 phyloge-
netic group and to a lesser extend from the D group
(15,16,30–34). It had been estimated in collections dating
from before the emergence of ESBL, or in collections not
selected for ESBL production, that group B2 strains
account for approximately two thirds of all extraintestinal
E. coli infections, including UTI, bacteremia, meningitis,
and other miscellaneous infections. When all ESBL-pro-
ducing  E. coli strains were considered, whatever their
types were, group B2 represented only 39.4% of the strains
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ESBLamong E. coli clinical strains isolated from infection
was associated with shifts in phylogenetic distribution
toward non-B2 phylogenetic groups, in particular groups
D and A. The distribution of group B2 among strains iso-
lated from infection or from colonization was not very dif-
ferent even if it was pointed out that subgroup B23 strains
had a tendency to be isolated more frequently in clinical
infections. Johnson et al., in 1991 (18), observed that E.
coli strains belonging to phylogenetic groups other than
group B2 have a greater prevalence of antimicrobial resist-
ance, such as to ampicillin, tetracycline, chloramphenicol,
streptomycin, and sulfonamide; express significantly
fewer virulence factors; and invade more commonly com-
promised hosts. ESBL-producing organisms, which are
resistant to β-lactams, except carbapenems and
cephamycins, and are often resistant to other antimicrobial
drugs, are responsible for nosocomial infections, mostly in
immunocompromised patients. ESBL-producing organ-
isms also frequently colonize the lower digestive tract, and
therefore are a major source for ESBL propagation (8).
This finding may explain why two thirds of the strains in
our study were not traditional virulence clones of ExPEC
but clones whose ability to cause infection is limited to
compromised hosts, in whom antibiotic resistance might
provide selective advantage. 
ESBLs are acquired β-lactamases that are encoded
mainly by genes located on plasmids (2). As such, they are
a recent evolutionary development. Even if the genetic ele-
ment that carries resistance is a mobile element, the multi-
dimentional analysis showed a preferential association
between the genetic background and the type of ESBLpro-
duced by the strains. Thus, an association was seen
between SHV type and subgroup B23, between TEM type
and subgroup B22, and CTX-M type and subgroup D2.
Even more, the pap, sfa/foc, and hly VFs were associated
with the genotype SHV type/subgroup B23, defining a
potentially high-virulence group of ESBL-producing E.
coli strains. In contrast, the genotype CTX-M type/sub-
group D2, characterized by a low VF score, defined a
potentially low-virulence group of ESBL-producing E.
coli strains. The type of ESBL produced by E. coli could
be a predictive factor for intrinsic virulence potential. 
Organisms that produce ESBL are frequently resistant
to other antimicrobial agents, such as aminoglycosides,
tetracycline, and trimethoprim-sulfamethoxazole, as many
of these additional resistance genes are encoded on the
ESBL-associated plasmid. Fluoroquinolone resistance,
which is also frequently associated with ESBL production,
is usually chromosomally encoded, unlike the other core-
sistances. However, plasmid-mediated quinolone resist-
ance has been discovered recently (35). Prevalence of
fluoroquinolone resistance among ESBL-producing strains
varies according to geographic regions (36), from 13.7% in
Canada to 65.5% in the western Pacific. In our study,
34.8% of strains were resistant, which is close to the preva-
lence (34.2%) reported in Europe (36). Correlation with
phylogenetic background and VF profiles showed highly
fluoroquinolone-resistant strains of subgroup D1, with the
lowest VF score and association with colonization. In con-
trast, strains of phylogenetic group B2, which had the
highest VF score, were among the strains with the lowest
fluoroquinolone-resistance rates. These data agree with the
work of Johnson et al. (19,37) and show a clear trade-off
between resistance to fluoroquinolones and virulence. In
addition, our study highlights an association between these
fluoroquinolone-resistant strains and CTX-M-producing
strains, which are devoid of VFs. However, the search for
the gene responsible for plasmid-mediated quinolone
resistance, qnr, by PCR was negative in our collection of
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Branger, unpub. data). Thus, the observed association is
not due to a genetic link between resistance to expanded-
spectrum β-lactams and quinolones on a mobile element,
as was recently reported (38).
During the last 2 decades, most of the ESBL found in
E. coli and, in general, in gram-negative bacilli, has been
of TEM or SHV lineage. Recently TEM and SHV types
have been replaced by CTX-M-type ESBL, whose emer-
gence and proliferation are particularly noteworthy (39).
The current spread may be explained in part by the ability
of some insertion sequence elements to mobilize and pro-
mote the expression of β-lactamase (40). However, the
high rate of fluoroquinolone resistance and the low viru-
lence of the strains carrying CTX-M ESBL could provide
them selective advantage to spread, especially under
strong environmental antimicrobial pressure with fluoro-
quinolones.
In summary, mobile elements encoding ESBL are not
randomly distributed among the genetic diversity of the E.
coli species. The arrival, expression, and maintenance of
such elements seem to be the result of complex interac-
tions between the type of ESBL, the phylogenetic back-
ground, the intrinsic virulence of the strains, and the
presence of associated fluoroquinolone resistance. Such
complexity reflects very likely the diversity of ecologic
niches with different selective pressures.
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